JPH0142267B2 - - Google Patents
Info
- Publication number
- JPH0142267B2 JPH0142267B2 JP4090282A JP4090282A JPH0142267B2 JP H0142267 B2 JPH0142267 B2 JP H0142267B2 JP 4090282 A JP4090282 A JP 4090282A JP 4090282 A JP4090282 A JP 4090282A JP H0142267 B2 JPH0142267 B2 JP H0142267B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- general formula
- halogen atom
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は次の一般式
(式中R1はハロゲン原子、ヒドラジノ基又は基
−NHR2,−OR2,−SR2又は
The present invention is based on the following general formula (In the formula, R 1 is a halogen atom, a hydrazino group, or a group -NHR 2 , -OR 2 , -SR 2 or
【式】を示す。
ここでR2は炭素数2以上のアルキル基、シク
ロアルキル基、アルケニル基、アルキニル基、ア
ラルキル基、フエニル基又はピリジル基を意味
し、R3及びR4は低級アルキルであつて、これら
は又相互に結合して、他の酸素原子又は窒素原子
を含むことのある異項環を形成してもよい)で表
われる新規なピリジン誘導体に関する。
一般式〔〕で表わされる化合物は、それ自体
抗炎症作用、鎮痛作用、抗血栓作用ないし制癌作
用等を有するばかりでなく、医薬の中間体として
も利用される物質を包含するものである。
本発明の化合物は、例えば次の一般式
(式中R1は前記と同一の意味を有し、R′は水素
原子又は低級アルキル基を示す)で表わされる化
合物とメチルアミンとを室温〜100℃で通常の酸
アミド形成反応を行なわせることにより得られ
る。
かくして得られる一般式〔〕の化合物中R1
がハロゲン原子であるものは、必要によりアミン
類、アルコール類又はチオアルコール類と所望に
より塩基性助剤を存在せしめて反応させることに
より、先にR1について定義したハロゲン原子以
外の基に変換せしめることができる。
又、同様に一般式〔〕におけるR1がアミノ
基あるいは水酸基である化合物を常法により式
R2X〔〕(式中R2は前記と同一の意味を有し、
Xはハロゲン原子を示す)で表わされる化合物と
反応させることによつても対応する一般式〔〕
の化合物に導くことができる。
実施例 1
4−クロロ−2,6−ピリジンジカルボン酸ジ
メチルエステル8gをメタノール30ml及び40%メ
チルアミン水溶液30mlに溶解し、室温で1時間放
置した後減圧下濃縮し、残渣を水洗後メタノール
水混合溶媒より再結晶して融点195〜7℃の4−
クロロ−N,N′−ジメチル−2,6−ピリジン
ジカルボン酸アミド7.1gを得た。
元素分析値 分子式C9H10ClN3O2として
C H N
理論値(%) 47.5 1.4 18.5
実測値(%) 47.2 4.6 18.6
実施例 2〜5
実施例1と同様にして表−1の化合物を得た。[Formula] is shown. Here, R 2 means an alkyl group, cycloalkyl group, alkenyl group, alkynyl group, aralkyl group, phenyl group, or pyridyl group having 2 or more carbon atoms, and R 3 and R 4 are lower alkyl, and these are also (which may be bonded to each other to form a heterocyclic ring that may contain other oxygen atoms or nitrogen atoms). The compounds represented by the general formula [] not only have anti-inflammatory, analgesic, antithrombotic, or anticancer effects per se, but also include substances that can be used as pharmaceutical intermediates. The compounds of the present invention may be, for example, represented by the following general formula: (In the formula, R 1 has the same meaning as above, and R' represents a hydrogen atom or a lower alkyl group) and methylamine are subjected to a usual acid amide forming reaction at room temperature to 100°C. It can be obtained by R 1 in the compound of the general formula [] thus obtained
is a halogen atom, it can be converted into a group other than the halogen atom defined above for R 1 by reacting it with amines, alcohols or thioalcohols in the presence of a basic auxiliary if desired. be able to. Similarly, a compound in which R 1 in the general formula [] is an amino group or a hydroxyl group can be converted to the formula
R 2 X [] (in the formula, R 2 has the same meaning as above,
The corresponding general formula [] can also be obtained by reacting with a compound represented by (X represents a halogen atom)
can lead to compounds of Example 1 8 g of 4-chloro-2,6-pyridinedicarboxylic acid dimethyl ester was dissolved in 30 ml of methanol and 30 ml of 40% methylamine aqueous solution, left at room temperature for 1 hour, concentrated under reduced pressure, washed the residue with water, and mixed with methanol and water. Recrystallized from a solvent to give 4-
7.1 g of chloro-N,N'-dimethyl-2,6-pyridinedicarboxylic acid amide was obtained. Elemental analysis value Molecular formula: C 9 H 10 ClN 3 O 2 C H N Theoretical value (%) 47.5 1.4 18.5 Actual value (%) 47.2 4.6 18.6 Examples 2 to 5 The compounds in Table 1 were prepared in the same manner as in Example 1. Obtained.
【表】
実施例 6
4−クロロ−N,N′−ジメチル−2,6−ピ
リジンジカルボン酸アミド3gをメタノール30ml
及びn−プロピルアミン10gと共に封管中100℃
で2日間加熱し、反応液を濃縮し、残渣を希塩酸
と混合し、不溶物を去する。液に炭酸カリウ
ムを加えてアルカリ性とし、析出する結晶をメタ
ノール−水混合溶媒より再結晶して、融点270〜
272℃の4−n−プロピルアミノN,N′−ジメチ
ル−2,6−ピリジンジカルボン酸アミド1.8g
を得た。
元素分析値 分子式C12H18N4O2として
C H N
理論値(%) 57.6 7.3 22.4
実測値(%) 57.7 7.4 22.6
実施例 7〜10
実施例6と同様にして表−2の化合物を得た。[Table] Example 6 3 g of 4-chloro-N,N'-dimethyl-2,6-pyridinedicarboxylic acid amide and 30 ml of methanol
and 10 g of n-propylamine in a sealed tube at 100°C.
The reaction mixture was heated for 2 days, the reaction solution was concentrated, and the residue was mixed with dilute hydrochloric acid to remove insoluble matter. Potassium carbonate is added to the liquid to make it alkaline, and the precipitated crystals are recrystallized from a methanol-water mixed solvent to give a melting point of 270~
1.8 g of 4-n-propylamino N,N'-dimethyl-2,6-pyridinedicarboxylic acid amide at 272°C
I got it. Elemental analysis value Molecular formula C 12 H 18 N 4 O 2 C H N Theoretical value (%) 57.6 7.3 22.4 Actual value (%) 57.7 7.4 22.6 Examples 7 to 10 Compounds in Table 2 were prepared in the same manner as in Example 6. Obtained.
【表】【table】
Claims (1)
−NHR2,−OR2,−SR2又は【式】を示す。 ここでR2は炭素数2以上のアルキル基、シク
ロアルキル基、アルケニル基、アルキニル基、ア
ラルキル基、フエニル基又はピリジル基を意味
し、R3及びR4は低級アルキルであつて、これら
は又相互に結合して、他の酸素原子又は窒素原子
を含むことのある異項環を形成してもよい)で表
われる化合物。[Claims] 1. General formula (In the formula, R 1 represents a halogen atom, a hydrazino group, a group -NHR 2 , -OR 2 , -SR 2 or [Formula]. Here, R 2 represents an alkyl group having 2 or more carbon atoms, a cycloalkyl group, or an alkenyl group. , an alkynyl group, an aralkyl group, a phenyl group or a pyridyl group, and R 3 and R 4 are lower alkyl, which are also bonded to each other and may contain other oxygen atoms or nitrogen atoms. (may form a ring).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4090282A JPS58159465A (en) | 1982-03-17 | 1982-03-17 | Pyridine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4090282A JPS58159465A (en) | 1982-03-17 | 1982-03-17 | Pyridine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58159465A JPS58159465A (en) | 1983-09-21 |
| JPH0142267B2 true JPH0142267B2 (en) | 1989-09-11 |
Family
ID=12593436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4090282A Granted JPS58159465A (en) | 1982-03-17 | 1982-03-17 | Pyridine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58159465A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4691018A (en) * | 1985-05-23 | 1987-09-01 | Chugai Seiyaku Kabushiki Kaisha | Pyridine derivatives and their use as anti-allergic agents |
-
1982
- 1982-03-17 JP JP4090282A patent/JPS58159465A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58159465A (en) | 1983-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2836041B2 (en) | Novel method for producing 1-phenylimidazoline-2,5-dione derivative | |
| JPS54130587A (en) | Carbostyryl derivative | |
| KR840002405A (en) | Method for preparing cephalosporin | |
| US4259344A (en) | Sulfur-containing benzimidazole derivatives | |
| EP0068407A1 (en) | Aminosulfonylbenzoic acid derivatives | |
| JPH0142267B2 (en) | ||
| JPS6251651A (en) | Manufacture of 3-aminoacrylic acid ester | |
| US2461950A (en) | or x-amino quinazolines | |
| US3388130A (en) | 1-hydrazino or 1-amino isoquinolines | |
| US2744119A (en) | Phthalyl-alanyl-mercaptoethyl amides and preparation thereof | |
| JPH061776A (en) | Production of substituted pyrazinecarbonitrile | |
| US862675A (en) | Orthodioxyphenylethanolamin. | |
| JPS6339893A (en) | 5-fluorouridine and production thereof | |
| IL44341A (en) | 6-substituted 3-carbethoxyhydrazinopyridazines their preparation and pharmaceutical compositions containing them | |
| JP2018158950A (en) | Method for producing 2-chloroacetoacetamide | |
| GB2053187A (en) | Process for preparing pyrenzepine | |
| JP3272340B2 (en) | Method for producing 1-[(cyclopent-3-en-1-yl) methyl] -5-ethyl-6- (3,5-dimethylbenzoyl) -2,4-pyrimidinedione | |
| JP3443584B2 (en) | Method for producing N-tert-butylpyrazinecarboxamides | |
| JPS61118372A (en) | Novel pyrimidine derivative and its preparation | |
| JPH0667934B2 (en) | Process for producing N-methyl derivative of lysergol and 10.alpha.-methoxylmyrisylgol | |
| JPS5935392B2 (en) | Method for producing benzonitriles | |
| JPS58154537A (en) | Preparation of hydroxybenzoic acid lower aralkyl ester | |
| JPS58152843A (en) | Preparation of hydroxybenzoic acid lower alkyl ester | |
| JPS61180751A (en) | Beta-(acetylamino)acrylic ester | |
| JPS5934712B2 (en) | 7-Hydroxy-2-nitrobenzofuran |